Amgen said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a label variation for Kyprolis (carfilzomib) to include updated overall survival data from the phase III head-to-head ENDEAVOR trial in patients with relapsed or refractory multiple myeloma (Kyprolis and dexamethasone versus Velcade [bortezomib] and dexamethasone).
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
